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The Finding of Premalignant Lesions is Not Associated with
Smoking Cessation in Chemoprevention Study Volunteers
Romane M. Schook, MSc, Berber B. M. Postmus, MSc, Remco M. van den Berg, MD, PhD,
Thomas G. Sutedja, MD, PhD, Frances S. Man de, MSc, Egbert F. Smit, MD, PhD,
and Pieter E. Postmus, MD, PhD
Background and Study Aims: Screening programs for lung cancer
may lead to a heightened awareness of the risks of smoking and
enhance quitting. The aim of this study was to evaluate whether the
participation on a chemoprevention study for premalignant lesions
could influence smoking cessation.
Methods: Two hundred one volunteers, current (n  188) and
former smokers (n  13) with more than 20 pack years had been
screened for the chemoprevention study. One hundred forty-six of
the current smokers at time of chemoprevention study screening
have been retrospectively interviewed about their smoking behavior
1 year after their first contact for the chemoprevention study.
Structured questionnaires were used, and interviews were held by
telephone. The quitters at the time of these first interviews were
contacted again 4 years after the initial interview about their current
smoking behavior.
Results: Of the 146 smoking volunteers, 83 were diagnosed with
premalignant lesions of the bronchial mucosa and participated in the
chemoprevention study, and 63 had no premalignant lesions and
were not included in that study.
The majority of participants were men: 87 (60%). The mean
age of the participants was 52  9 years, and the mean age at which
volunteers started smoking was 15  3. Mean number of pack years
was 47  27. Ten volunteers in the group without premalignant
lesions and 19 in the group with premalignant lesions had quit
smoking at time of the first interview. The smoking cessation rate of
the total study group was 20%.
Univariate logistic regression analysis demonstrated that
smoking cessation was only significantly associated with male
gender. No significant associations were found between smoking
cessation and the finding of premalignant lesions, sex, age, level of
addiction, educational level, marital condition, history of cancer/
pulmonary diseases, age at start smoking, previous attempts to quit
smoking, and motivation to quit smoking.
Within the group of subjects who had quit smoking at the
time of the first interview, 15 of 29 persons who had stopped
smoking at the time of the first interview have reported that partic-
ipation in the bronchoscopy screening and/or the trial has been of
major influence on their decision to stop smoking.
Conclusions: A smoking cessation rate of 20% has been found
among volunteers for a chemopreventive trial investigating smok-
ing-related premalignant lesions after almost 2 years after initial
contact has been found. Volunteers experienced screening and trial
participation as having influenced their smoking cessation. Smoking
cessation was significantly associated with male gender, whereas the
finding of premalignant lesions by bronchoscopy was not.
Key Words: Screening, Bronchoscopy, Smoking cessation, Prema-
lignant lesions, Chemoprevention study.
(J Thorac Oncol. 2010;5: 1240–1245)
Smoking is a major causative factor of cardiovasculardisease and the most important cause of lung cancer.1–3
Ninety percent of patients with lung cancer are (former)
smokers,1 and in Europe, Japan, and North America, be-
tween 87% and 91% of lung cancers in men and between
57% and 86% of lung cancers in women are attributable to
smoking.4–6
Because cardiovascular diseases and lung cancer are
among the most important causes of mortality in the
western countries,7,8 reduction of the number of smokers
would be of great benefit for public health. Smoking
cessation is the best preventive measure for these smoking-
related diseases. Nevertheless, despite the knowledge that
smoking is a harmful habit, multiple messages on cigarette
boxes, antismoking campaigns, and scientists’ and doctors’
warnings,9–11 there are still many smokers,12–14 and only a small
percentages of smokers succeed to quit permanently. Despite a
minor reduction in the number of smokers during the last
decade, still around 25% of the adult population smoked in the
Netherlands in 2007.15 Furthermore, smoking cessation has
proven to be extremely difficult to achieve. Even with counsel-
ing and nicotine replacement therapy, the success rate remains
low.16–18
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Another way to reduce smoking-related mortality is
secondary prevention, i.e., screening for smoking-related dis-
eases. Screening for lung cancer with different screening
modalities aims at detecting the disease at an early stage, so
that treatment may be more effective. Screening for early-
stage lung cancer may result in a high actuarial survival rate
in selected volunteers,19 but whether screening is truly effec-
tive still needs to be proven in (ongoing) randomized con-
trolled trial (RCTs).20
Screening programs for smoking-related diseases may
also lead to heightened awareness of the risks of smoking
among participants and thus help reduce the number of
smokers. On the other hand, it could be argued that smokers
participating in a screening program are aware of the dangers
of smoking and may get a false sense of security when results
of screening do not demonstrate abnormalities and cause
them to lose their motivation to stop.
Some studies have shown that participants in computed
tomography (CT) screening programs quit smoking more
often when abnormal findings (usually of unknown signifi-
cance) were present. Cessation rates were high.21,22
At the beginning of February 2002, a chemoprevention
study was initiated at the VU University Medical Center
(VUMC) and the Netherlands Cancer Institute (NKI) in
Amsterdam, The Netherlands. Volunteers with at least 20
pack years of smoking were screened by bronchoscopy and
when a premalignant lesion was present, enrolled in a double-
blinded placebo-controlled phase II study.23
The goal of this study is to evaluate whether partici-
pating in the aforementioned study and the knowledge of the
presence of premalignant lesions enhanced cessation rate. We
hypothesized that volunteers who underwent screening by
bronchoscopy and participated to the trial because they had
premalignant lesions were more likely to quit smoking than
volunteers who did not.
PATIENTS AND METHODS
Subjects
Between February 2002 and October 2004, 201 current
and former smokers were screened for a double-blinded RCT
of the inhalation corticosteroid fluticasone dipropionate to
study its effect on bronchoscopically detected premalignant
lesions in the bronchial mucosa.23,24 Volunteers were re-
cruited by repeated advertisement in (local) newspapers,
information folders at the VUMC hospital and NKI hospital
or asked by their pulmonary physician of the VUMC or NKI
hospital whether they wanted to participate.
Inclusion criteria for this chemoprevention study were
healthy volunteers, current or former smokers, with a smoking
history of more than 20 pack years. Patients who had undergone
treatment with curative intent of head and neck or lung cancer of
any stage and did not show any sign of recurrence on CT were
also asked to participate. Exclusion criteria were serious comor-
bid disease, forced expiratory volume in 1 second values below
1000 mL, or use of systemic or inhaled corticosteroids in the
year before enrollment.
The inclusion criteria of this study were as follows: all
volunteers who were screened by bronchoscopy for the afore-
mentioned trial and smoked at the time of screening (t0).
Exclusion criteria were also formulated: former smokers at t0
were excluded, because their decision to quit smoking was
taken before their response to participate in the chemopre-
vention study. Volunteers who fulfilled inclusion criteria
according to our data but seemed not to have undergone any
bronchoscopy were excluded as well (Figure 1: flow chart).
At least 1 year after the initial contact for screening for
the fluticasone study (mean time period between initial con-
tact and first interview was 21 7 months, time period of this
contact for first interviews abbreviated as t1), we approached
all persons who had undergone bronchoscopy and partici-
pated in the RCT and those who had undergone bronchos-
copy but were not eligible for the chemoprevention trial
because they had no premalignant lesions.
These volunteers received a letter from our institu-
tion and were approached by phone at least 1 week later.
When the volunteers were reached by telephone, they were
first asked whether they had received the letter announcing
this study in continuation of the previous one. If not,
Screening: 201 
subjects
Subjects reached
n=190
Subjects not 
reached n=11
Subjects giving 
consent for 
interviews n=182
Subjects not giving 
consent n=8
Excluded for 
analysis n=36
No intervention* n=28
Former smokers at t0̐ n=2
No intervention and former 
smokers n=6
Subjects interviewed 
n=182
Analyzed n=146
History of cancer n=15
Healthy volunteers n=131
Interview 1
(t1)̐
Excluded subjects 
n=117
Smokers at t1̐ n=117
Formers smokers at 
t1̐ n=29
Subjects giving 
consent, interviewed 
and analyzed n=26
Interview 2
(t2)̐ Excluded subjects 
n=3
Subjects not reached n=1
Dead subjects n=2
̐
̐
̐
̐̐
FIGURE 1. Flow chart of study volunteers. *No interven-
tion: volunteers had received information only and were nei-
ther screened by bronchoscopy nor included in the trial. t0
is the time of screening for the Fluticasone study, time at
which volunteers had neither started yet with investigations
nor had undergone any bronchoscopy, t1 is the time of the
first interviews, and t2 is the time of the second interviews.
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explanation about this study was given, and volunteers
were asked to participate. If they had received the letter,
they would immediately be asked to participate. The vol-
unteers were retrospectively interviewed by phone using
standardized questionnaires regarding several issues in-
cluding their smoking status. Usually, the interviews took
place at the first telephone contact.
Around 4 years after the initial contact for screening for
the fluticasone study (mean time period between initial con-
tact and second interview was 54  8 months), we ap-
proached once again, following the same strategy as men-
tioned previously, volunteers who were former smokers at
t1, for a second retrospective, structured interviews by
telephone regarding their present smoking status (at
present time period, contact for second interviews, abbre-
viated as t2).
Interviews
The first interviews took place by telephone by Berber
B.M. Postmus and Romane M. Schook in the period of June
2005 until February 2006 (t1).
The questionnaire contained 35 open- or multiple
choice questions and statements concerning demographic
data, level of education, medical history, motivation to par-
ticipate in the fluticasone trial, smoking history, smoking
behavior, and subjective experience of burden by bronchos-
copy (scale from 1 until 10, with 1: no burden at all and 10:
great burden).
Concerning their smoking behavior participants were
asked “Do you smoke at the moment?” If they answered
“yes,” they were asked, “How many cigarettes do you smoke
in a day?” If “no,” they were asked “To what extent did
volunteering and/or participating in the fluticasone study
make you quit smoking?” Participants could answer (1) not at
all, (2) to some extent, or (3) to a major extent.
The second interviews with former smokers at t1 took
place by telephone by R.M.S. from June 2008 until August
2008 (t2), with a set of seven questions derived from the first
questionnaire to assess their smoking behavior once again
and the influence of the fluticasone trial on their decision to
quit smoking and to keep refraining from smoking.
Data on smoking cessation were based only on partic-
ipants’ answers to the interview questions.
Statistical Analysis
We performed descriptive analyses, and we used 2
tests and independent t tests to identify differences in demo-
graphics between our study groups. Regression analysis was
performed to analyze which factors were associated with
smoking cessation.
All analyses were conducted using SPSS version 15.0.
RESULTS
Participant Characteristics
Data of the 201 volunteers who had been screened for
the chemoprevention study were at our disposal. Eleven
subjects could not be reached, eight did not give their consent
for the interviews, and 36 were excluded because they were
former smokers at t0 and/or seemed to have not undergone
any kind of intervention (bronchoscopy/trial participation).
Ultimately, we interviewed 146 subjects for this smoking
behavior study (Figure 1: flow chart). The study participants
have been divided into two groups (Table 1). Group 1
TABLE 1. Characteristics of Study Population
Item
Total
(n  146)
Group 1
(n  63)
Group 2
(n  83)
p Value
(Group 1
vs. 2)
Demographics
Gender (M/F) 87/59 31/32 56/27 0.026a
Age (yr) (mean  SD) 52  9 52  9 53  9 0.702
Level of education (high vs.
low)b
68/78 31/32 37/46 0.579
Marital condition (single/
partner)
80/66 36/27 44/39 0.619
History of asthma and/or
COPD (yes/no)
19/127 8/55 11/72 0.921
History of malignancy
(yes/no)c
15/131 4/59 11/72 0.174
History of malignancy in the
family (yes/no)
90/56 39/24 51/32 0.955
Location (VUMC/NKI) 61/85 23/40 38/45 0.260
Smoking habits
Age start smoking (yr)
(mean  SD)
15  3 15  3 14  3 0.067
Pack years (mean  SD) 47  27 38  17 55  30 0.007a
No. of cigarettes per day at
time (t0)d
27  13 24  12 30  13 0.015a
Current number of cigarettes
per day if smoker,e at time
of first interview (t1)d
22  13 20  13 24  12 0.146
Previous attempts to quit
smoking (yes/no)
119/27 52/11 67/16 0.779
Motives for trial participation
Smoking cessation wish as
reason for participation
(yes/no)
52/94 26/37 26/57 0.260
Interest in current health as
reason for participation
(yes/no)
58/61 40/23 45/38 0.214
Other
Burden of bronchoscopyf
(mean  SD)
6.0  2.5 5.6  2.6 6.2  2.4 0.127
a Significant, p  0.05.
b High education: university degree and higher professional education. Low edu-
cation: primary school, junior/senior high school, junior, and senior secondary voca-
tional education.
c In the group without premalignant lesions, no volunteer had suffered from
smoking related cancers (lung and head and neck cancer) and four from other cancer
types (one lymphoma, one skin, and two breast cancers). In the group with premalignant
lesions, four volunteers had suffered from head and neck cancer and seven from other
cancer types (one lymphoma, two testis, one skin, two breast cancers, and one
unknown).
d t0 is the time of screening for the Fluticasone study, time at which volunteers had
neither started yet with investigations nor had undergone any bronchoscopy. t1 is the
time of the first interviews and t2 the time of the second interviews.
e Group without premalignant lesions: n 53 and group with premalignant lesions:
n  64, total: n  117.
f Experienced burden of bronchoscopy: 1 no burden at all and 10 great burden.
In the group with premalignant lesions (n 62), one patient could not remember his/her
experienced burden of bronchoscopy because of brain damage due to epilepsy.
COPD, chronic obstructive pulmonary disease; NKI, Netherlands Cancer Institute;
VUMC, VU University Medical Center; SD, standard deviation.
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consisted of 63 subjects who were excluded from the RCT
because they had no premalignant endobronchial lesions
found at bronchoscopy, and group 2 consisted of 83 subjects
who had participated in RCT because they fulfilled all inclu-
sion criteria including the presence of premalignant endo-
bronchial lesions.
The majority of participants were men: 87 (60%).
There were significantly more men in the group with prema-
lignant lesions. There were no significant differences in
history of malignancies between the group with (n  11) and
the group without premalignant lesions (n  4).
The mean age of all participants was 52  9 years, and
the mean age at which subjects started smoking was 15  3
years. Mean number of pack years was 47  27. At time of
the first interview (t1), the mean number of cigarettes smoked
per subject was 22  13/d, which is less than at the time of
screening for the fluticasone study t0 (27  13/d). The
number of pack years and the number of cigarettes smoked
per day at t0 was significantly higher in the group with
premalignant lesions.
Smoking Cessation
At the time of the first interview (t1), 10 subjects in the
group without premalignant lesions and 19 in the group with
premalignant lesions had quit smoking. The smoking cessa-
tion rates are 16% and 23%, respectively. The smoking
cessation rate of the total study group was 20%.
Smoking Cessation Factors
Univariate logistic regression analysis (Table 2) dem-
onstrated that smoking cessation was only significantly asso-
ciated with male gender. Number of attempts to quit smoking
in the past tended to show an association with smoking
cessation but did not reach significance. The presence of
premalignant lesions was not significantly associated with
smoking cessation. Other factors of Table 2 did not show any
significant associations with smoking cessation.
Bronchoscopy
Volunteers who underwent at least one bronchoscopy
were asked to grade their subjective experience on a scale
from 1 until 10 (with 1: no burden at all and 10: great burden).
Mean subjective experience in the group of former smokers at
time of first interview was 6.0  2.2 and in the current
smokers 6.0  2.5. Mean subjective experience in group 1
(n  62, 1 person could not remember her experience with
bronchoscopy) was 6.0  2.6 and 6.2  2.4 in group 2 (n 
83). Independent t tests did not show any significant differ-
ence between participant groups and between former smokers
and current smokers at time of the first interviews.
Opinions About Trial Influence
Within the group of subjects who had quit smoking at
t1, 15 of 29 subjects have reported screening with bronchos-
copy and/or trial participation of a major influence on their
decision for smoking cessation. One subject answered “do
not know,” nine answered “no influence,” and four “some
influence.” Among participants who had premalignant le-
sions, 74% (14/19) considered participation in the trial as a
major influence on their smoking behavior. The reported trial
influence (n  28) (influence or no influence) on smoking
cessation and the fact of having premalignant lesions or not
tended to show a relationship but did not reach significance
with a 2 test (p  0.097) (Table 3).
TABLE 2. Univariate Regression Analysis
Variable
Odds
Ratio 95% CI p
Malignant lesions 1.573 0.674–3.637 0.295
Gender (female) 0.315 0.119–0.830 0.020a
Age (yr) 0.988 0.945–1.033 0.602
Pack years 1.008 0.994–1.022 0.287
Educational level 1.089 0.482–2.458 0.838
Marital condition 1.387 0.614–3.132 0.432
History of cancer 1.542 0.453–5.246 0.488
History of asthma and/or
COPD
1.088 0.332–3.564 0.889
History of cancer in
family
1.023 0.443–2.363 0.958
Burden of bronchoscopy 1.000 0.848–1.180 1.000
Age at starting smoking 0.916 0.794–1.058 0.233
Cigarettes per day at
screening
1.015 0.986–1.045 0.314
Smoking cessation wish as
reason for participation
0.774 0.324–1.852 0.566
Interest in current health as
reason for participation
0.719 0.318–1.628 0.429
Attempt to quit smoking 0.404 0.159–1.027 0.057b
a p  0.05.
b p  0.1.
CI, confidence interval; COPD, chronic obstructive pulmonary disease.
TABLE 3. Trial Influence on Smoking Cessation per Group
Trial Influence Yes (N) (%)
Quitters after t0 at t1a
Total (n  28) 19 (68)
Group 1b (n  9) 4 (44)c
Group 2d (n  19) 15 (79)c
Quitters at t1 reevaluated at t2a
Total (n  19) 12 (63)
Group 1 (n  7) 3 (43)
Group 2 (n  12) 9 (75)
Relapse smokerse at t2a
Total (n  7) 4 (57)
Group 1 (n  2) 0
Group 2 (n  5) 4 (80)
Former and relapse smokerse at t2a
Total (n  26) 16 (61)
Group 1 (n  9) 3 (33)f
Group 2 (n  17) 13 (77)f
a t1 is the time of the first interviews and t2 the time of the second interviews.
b Group 1: group without premalignant lesions.
c p  0.1.
d Group 2: group with premalignant lesions.
e Relapse smokers are volunteers who had quit smoking at t1 but smoked again at t2.
f p  0.05.
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Second Interviews (t2)
Of the 29 subjects who were former smokers at the time
of the first interview (t1), 26 subjects were interviewed again
(Figure 1: flow chart). One subject could not be reached, and
two subjects had died (causes of death: car accident and
metastasized posterior tongue carcinoma).
Of the subjects participating in the second interview
(n 26), 19 (73%) (still) did not smoke at time of the second
interview t2; this is 13% of our total study population, and
gives smoking cessation rates of 11% for the group without
premalignant lesions and 14% for the group with premalig-
nant lesions.
Three of the “refrainers” had resumed smoking after a
period of abstinence following trial participation but had quit
again at t2.
Of the total group of former smokers at t1 (n  26), 16
(62%) still considered the trial as an influencing factor on
their smoking behavior. A 2 test between the reported trial
influence (influence versus no influence) and the fact of
having premalignant lesions or not showed a significant
relationship at t2 (p  0.046), p  0.05.
DISCUSSION
This quitting rate of 20% among volunteers for a chemo-
preventive trial after almost 2 years since initial contact was
higher than what is normally found after active smoking cam-
paigns among the general population,12,25 although we must
emphasize that we are looking at a selected study group and
comparable with what was found in other studies aimed at
screening for lung cancer by the use of CT scan screening:
Townsend et al.21,22 24 to 42% and Ostroff et al. 23%.
There seemed to be an association between trial partici-
pation and smoking cessation because volunteers included in the
trial showed a higher smoking cessation rate than volunteers
excluded. The distinguishing factor between these two groups
and determinant of trial inclusion was the finding of premalig-
nant lesions at bronchoscopy. Because other studies had shown
that having smoking-related diseases, experiencing smoking-
related symptoms, or having smoking-related damage resulted in
higher smoking cessation rates,26–28 we assumed that the sup-
posed association between smoking cessation and the presence
of premalignant lesions was reliable. Nevertheless, this associ-
ation was not statistically significant.
Of all known factors related with smoking cessation,
only male gender was significant.27,29 There was a trend of
higher cessation rates if premalignant lesions were found,
which is contrary to what one might expect as the level of
addiction (indicated with pack years and number of cigarettes
smoked per day) is associated with smoking behavior29–31
and differed significantly in both groups at baseline. Other
factors such as level of interest in quitting smoking, age of
starting smoking, age of participant, education, marital status,
history of cancer or lung diseases, and previous attempts to
quit smoking25,27,29–31 were not significant. Small sample size
might play an important role in these findings. We may be
confronted with a low statistical power as a consequence of
the retrospective study design.
Knowing that an initially strong motivation to quit smok-
ing disappears quickly,32 even in patients being diagnosed with
cancer, one might expect that having premalignant lesions is not
likely to be a very strong motivation to stop.
Because of its invasive character and reported
patients’anxiety, fear of pain, and breathing difficulties dur-
ing bronchoscopy,33 and the fear for cancer diagnosis after
the diagnostic intervention,34 we expected that the experience
of bronchoscopy would affect a patient’s smoking habits.
Nevertheless, it is unlikely that the (unpleasant) experience of
a bronchoscopy as a single factor is associated to quitting
smoking in this study, because we have found no significant
difference between the subjective burden of a bronchoscopy
between former smokers at t1 and volunteers who never quit
smoking. Smit et al.35 and Scholte op Reimer et al.36 also
have found that despite a major smoking-related event, such
as a pneumothorax or an acute myocardial infarction, many
people continue to smoke.
Our study also has other limitations beside the number
of participants. First, our results are based on participants’
answers. Participants may have given more socially accept-
able answers about their smoking behavior out of shame for
their addiction. Furthermore, we did not determine criteria to
define the “former smoker” in unit of time (e.g., volunteers
are classified as former smoker if they have refrained from
smoking during 3 months). Thus, we can only trust partici-
pants’ answers and consider them as former smokers if they
have said so. Also, we only have contacted the volunteers
who were former smokers at time of the first interview (t1)
twice. “Current smokers” at t1 have been contacted just once.
As the smoking behavior of the smokers at time of first
interviews is unknown for the second interviews, an under-
estimation of the smoking cessation is possible, although it
seems improbable that smokers at t1 would have quit smok-
ing at t2, considering that smoking cessation is very difficult
to achieve despite motivation.37 Fortunately, there is no
indication that reassurance (informing a subject that no ab-
normalities were found) leads to more dangerous behavior
(i.e., smoking). Participants of the group without premalig-
nant lesions smoked less at t1 than at trial screening time (t0).
The drop in persistent quitters between t1 and t2 con-
firms the need for prolonged support to prevent relapse.
CONCLUSIONS
We found a smoking cessation rate of 20% among
volunteers for a chemoprevention trial investigating smoking-
related premalignant lesions almost 2 years after initial con-
tact. Volunteers experienced screening and trial participation
as influencing smoking cessation. Smoking cessation was
significantly associated with male gender, whereas the find-
ing of premalignant lesions by bronchoscopy was not.
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